High incidence combination of multiple primary malignant tumors of the digestive system

BACKGROUND Clinical reports of multiple primary malignant tumors (MPMTs) in the digestive system are increasing. In China, although the survival rate of patients with MPMTs is increasing, the quality of life is very low. Many patients have reached the advanced stage when the second primary tumor is found, resulting in no early intervention and treatment. This is due to the misunderstanding of MPMTs by clinicians, who treat such tumors as metastases. Therefore, before a patient has a second primary tumor, doctors should understand some common combinations of digestive system MPMTs to provide clinical guidance to the patient. AIM To explore the high incidence combination of digestive system MPMTs under heterochronism and synchronization. METHODS A total of 1902 patients with MPMTs at Peking Union Medical College Hospital were analyzed retrospectively. They were divided into metachronous MPMT and synchronous MPMT groups, and then the high incidence combinations of the first primary cancer and the second primary cancer in metachronous cancer and synchronous cancer were sorted. Sex and age differences between metachronous and synchronous tumors were tested by the chi square test and t test, respectively. A P value < 0.05 was considered as statistically significant, and SPSS version 26.0 (SPSS Inc., Chicago, Illinois, United States) was used for statistical analysis. RESULTS Among the 1902 patients with MPMTs confirmed by pathology, 1811 (95.2%) cases were secondary primary cancers, 89 (4.7%) cases were tertiary primary cancers, and 2 (0.1%) cases were quaternary primary cancers. Most (88.2%) of the secondary primary cancers were identified as metachronous multiple primary cancers six months after diagnosis of the first primary cancer. The top ten most common MPMTs in the first primary cancer group ranged from high to low as follows: Breast cancer, thyroid cancer, nonuterine cancer, lung cancer, colon cancer, kidney cancer, uterine cancer, bladder cancer, rectal cancer, and gastric cancer. The highest incidence rate of the first primary cancer in male metachronous cancer was lung cancer (11.6%), the highest incidence rate of the second primary cancer was still lung cancer (24.9%), the highest incidence rate of the first primary cancer in female metachronous cancer was breast cancer (32.7%), and the highest incidence rate of the second primary cancer was lung cancer (20.8%). Among them, breast cancer, nonuterine cancer and uterine cancer were female-specific malignant tumor types, and thyroid cancer also accounted for 79.6% of female patients. The top five metachronous cancer combinations, independent of female-specific malignant tumor types and thyroid cancer, were colon cancer and lung cancer (26 cases), kidney cancer and lung cancer (25 cases), rectal cancer and lung cancer (20 cases), gastric cancer and lung cancer (17 cases), and bladder cancer and lung cancer (17 cases). The most common synchronous cancer combination was colon cancer and rectal cancer (15 cases). CONCLUSION Screening for lung cancer should be performed six months after the detection of colon cancer while rectal cancer screening should be performed within six months.

[1]  Li Zhang,et al.  Second primary tumor after immune checkpoint inhibitor therapy: A case report , 2022, Thoracic cancer.

[2]  G. Che,et al.  Primary Lung Cancer After Treatment for Breast Cancer , 2021, International journal of women's health.

[3]  Fei Liu,et al.  Second primary malignancy among malignant solid tumor survivors aged 85 years and older , 2021, Scientific Reports.

[4]  S. Novello,et al.  Major breakthroughs in lung cancer adjuvant treatment: Looking beyond the horizon. , 2021, Cancer treatment reviews.

[5]  B. Suktitipat,et al.  Risks and cancer associations of metachronous and synchronous multiple primary cancers: a 25-year retrospective study , 2021, BMC Cancer.

[6]  J. Inadomi,et al.  Screening and prevention of colorectal cancer , 2021, BMJ.

[7]  A. Baheti,et al.  Follow-up of colorectal cancer and patterns of recurrence. , 2021, Clinical radiology.

[8]  Haifeng Xu,et al.  Downstaging and resection of hepatocellular carcinoma in patients with extrahepatic metastases after stereotactic therapy. , 2021, Hepatobiliary surgery and nutrition.

[9]  S. Cao,et al.  Case Report: Triple Primary Malignant Tumors of the Esophagus, Stomach, and Colon in a Patient With Genetic Analysis , 2021, Frontiers in Genetics.

[10]  Baoan Chen,et al.  Progress of Breast Cancer basic research in China , 2021, International journal of biological sciences.

[11]  K. Sawanyawisuth,et al.  Epithelial–Mesenchymal Transition in Liver Fluke-Induced Cholangiocarcinoma , 2021, Cancers.

[12]  M. Haigis,et al.  Metabolites and the tumour microenvironment: from cellular mechanisms to systemic metabolism , 2021, Nature Metabolism.

[13]  Yazan Abdeen,et al.  Four synchronous primary tumors in a male patient , 2021, Journal of cancer research and therapeutics.

[14]  Haitao Zhao,et al.  Conversion surgery for hepatocellular carcinoma in the new era of targeted and immune checkpoint inhibitor therapies. , 2020, Hepatobiliary surgery and nutrition.

[15]  Xian Shen,et al.  Long noncoding RNAs: functions and mechanisms in colon cancer , 2020, Molecular Cancer.

[16]  E. Neri,et al.  Imaging alternatives to colonoscopy: CT colonography and colon capsule. European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Gastrointestinal and Abdominal Radiology (ESGAR) Guideline – Update 2020 , 2020, European Radiology.

[17]  T. Houston Screening for Lung Cancer. , 2020, The Medical clinics of North America.

[18]  R. Coppes,et al.  Prevention and treatment of radiotherapy‐induced side effects , 2020, Molecular oncology.

[19]  Haitao Zhao,et al.  Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma. , 2020, Hepatobiliary surgery and nutrition.

[20]  C. la Vecchia,et al.  Progress in cancer mortality, incidence, and survival: a global overview. , 2020, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[21]  R. Weichselbaum,et al.  Methodological Development of Combination Drug and Radiotherapy in Basic and Clinical Research , 2020, Clinical Cancer Research.

[22]  J. Gregg,et al.  Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity , 2020, JCO precision oncology.

[23]  M. Santoro,et al.  RET Gene Fusions in Malignancies of the Thyroid and Other Tissues , 2020, Genes.

[24]  R. Kurzrock,et al.  Review of precision cancer medicine: Evolution of the treatment paradigm. , 2020, Cancer treatment reviews.

[25]  S. Singhal,et al.  Primary HPV screening for cervical cancer. , 2020, Best practice & research. Clinical obstetrics & gynaecology.

[26]  V. Arndt,et al.  The relative risk of second primary cancers in Switzerland: a population-based retrospective cohort study , 2020, BMC Cancer.

[27]  E. Wang,et al.  Cancer biomarker discovery for precision medicine: new progresses. , 2020, Current medicinal chemistry.

[28]  Zhitong Bing,et al.  Survival between synchronous and non-synchronous multiple primary cutaneous melanomas—a SEER database analysis , 2020, PeerJ.

[29]  I. Witz,et al.  The Tumor Microenvironment , 2012 .

[30]  Yongheng Chen,et al.  Nanotechnology in cancer diagnosis: progress, challenges and opportunities , 2019, Journal of Hematology & Oncology.

[31]  Heying Zhang,et al.  Multiple metachronous rare primary malignant tumors: A case report , 2019, Thoracic cancer.

[32]  R. Bast,et al.  Novel Approaches to Ovarian Cancer Screening , 2019, Current Oncology Reports.

[33]  M. Copur,et al.  Multiple Primary Tumors Over a Lifetime. , 2019, Oncology.

[34]  Haitao Zhao,et al.  Systemic management for patients with hepatobiliary tumors in a multi-dimensional view. , 2019, Hepatobiliary surgery and nutrition.

[35]  S. Fedewa,et al.  Cancer screening in the United States, 2019: A review of current American Cancer Society guidelines and current issues in cancer screening , 2019, CA: a cancer journal for clinicians.

[36]  A. Lenis,et al.  Second primary lung cancer in United States Cancer Survivors, 1992–2008 , 2019, Cancer Causes & Control.

[37]  A. Lenis,et al.  Second primary lung cancer in United States Cancer Survivors, 1992–2008 , 2019, Cancer Causes & Control.

[38]  Z. Zeng,et al.  Analysis of status and countermeasures of cancer incidence and mortality in China , 2019, Science China Life Sciences.

[39]  L. Duska,et al.  Cancer Screening and Prevention Highlights in Gynecologic Cancer. , 2019, Obstetrics and gynecology clinics of North America.

[40]  B. Sprague,et al.  A Linkage Between Thyroid and Breast Cancer: A Common Etiology? , 2018, Cancer Epidemiology, Biomarkers & Prevention.

[41]  V. Schirrmacher From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review) , 2018, International journal of oncology.

[42]  Wanqing Chen,et al.  Epidemiology of lung cancer in China , 2018, Thoracic cancer.

[43]  D. Tan,et al.  Clinical genetic testing outcome with multi-gene panel in Asian patients with multiple primary cancers , 2018, Oncotarget.

[44]  P. Trott,et al.  International Classification of Diseases for Oncology , 1977 .

[45]  S. Warren Multiple primary malignant tumors. A survey of the literature and a statistical study , 1932 .